Phospho-HER2/ErbB2 (Tyr1139) Antibody [L15E14]

Catalog No.: F2902

Application: Reactivity: Human

当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:500 - 1:1000 IP1:30

Application
WB, IP

Source
Rabbit Monoclonal Antibody

Reactivity
Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
137 kDa 185 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
Phospho-HER2/ErbB2 (Tyr1139) Antibody [L15E14] detects endogenous levels of total HER2/ErbB2 protein only when it is phosphorylated at Tyr1139.

Clone
L15E14

Synonym(s)
CD340, HER2, MLN19, NEU, NGL, ERBB2, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, MLN 19

Background
Phospho‑HER2/ErbB2 (Tyr1139) denotes the activated receptor tyrosine kinase ERBB2 phosphorylated at a specific C‑terminal tyrosine that serves as a docking site for SH2‑domain adaptors and shapes downstream signaling output. HER2 is a member of the EGFR/ErbB family that forms ligand‑independent homodimers when overexpressed or heterodimers with ligand‑bound partners such as EGFR and HER3, and autophosphorylation across multiple cytoplasmic tyrosines follows trans‑activation of its intracellular kinase domain. Tyr1139 lies within the intracellular tail among a cluster of autophosphorylation sites and, when phosphorylated, directly binds the SH2‑domain adaptor GRB7, creating a specific recruitment platform distinct from the ERBIN‑binding Tyr1248 or CBL‑binding Tyr1112 sites. GRB7 association with phospho‑Tyr1139 links activated HER2 to focal adhesion components and small GTPase signaling, and has been connected to cell migration, adhesion remodeling, and polarity disruption in HER2‑overexpressing models where Tyr1139 and Tyr1196 are robustly phosphorylated. HER2 overexpression in breast and other carcinomas results in constitutive phosphorylation of multiple tail tyrosines, including Tyr1139, and high levels of phosphorylated HER2 correlate with increased lymph node involvement, higher proliferation indices, and shorter disease‑free and disease‑specific survival compared with HER2 expression alone.

Background

Phospho‑HER2/ErbB2 (Tyr1139) denotes the activated receptor tyrosine kinase ERBB2 phosphorylated at a specific C‑terminal tyrosine that serves as a docking site for SH2‑domain adaptors and shapes downstream signaling output. HER2 is a member of the EGFR/ErbB family that forms ligand‑independent homodimers when overexpressed or heterodimers with ligand‑bound partners such as EGFR and HER3, and autophosphorylation across multiple cytoplasmic tyrosines follows trans‑activation of its intracellular kinase domain. Tyr1139 lies within the intracellular tail among a cluster of autophosphorylation sites and, when phosphorylated, directly binds the SH2‑domain adaptor GRB7, creating a specific recruitment platform distinct from the ERBIN‑binding Tyr1248 or CBL‑binding Tyr1112 sites. GRB7 association with phospho‑Tyr1139 links activated HER2 to focal adhesion components and small GTPase signaling, and has been connected to cell migration, adhesion remodeling, and polarity disruption in HER2‑overexpressing models where Tyr1139 and Tyr1196 are robustly phosphorylated. HER2 overexpression in breast and other carcinomas results in constitutive phosphorylation of multiple tail tyrosines, including Tyr1139, and high levels of phosphorylated HER2 correlate with increased lymph node involvement, higher proliferation indices, and shorter disease‑free and disease‑specific survival compared with HER2 expression alone.

References
[1] Menju T, et al. PLoS One. 2011;6(9):e25301. [2] Landgraf R. Breast Cancer Res. 2007;9(1):202.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%